Document is current
Any future updates will be listed below
-
Authors
Hu, Z. Ian
O’Reilly, Eileen M. http://orcid.org/0000-0002-8076-9199
- License Information
-
More Information
Article History
Accepted: 15 August 2023
First Online: 5 October 2023
Competing interests
: Z.I.H. declares no competing interests. E.M.O. receives institutional research funding from Genentech-Roche, Celgene–Bristol-Myers Squibb, BioNTech, AstraZeneca, Arcus, Elicio Therapeutics, Parker Institute, and Pertzye and has consulting, advisory and/or Steering Committee roles for Boehringer Ingelheim, BioNTech, Ipsen, Merck, Novartis, AstraZeneca, BioSapien, Astellas, BMS, Thetis, Autem, Novogene, Tempus, Agios, Genentech-Roche, Eisai, Merus, Genentech-Roche, Servier, Syros, and Leap Therapeutics.
